Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Aromatic hydrazones from Uniroyal with anti-HIV-1 activity encompassing mutant strains

July 12, 1999

BTG acquires novel technology for treatment of HIV

July 12, 1999

Pediatric formulation of Viramune now available in the E.U.

July 9, 1999

Boston Biomedica awarded SBIR grant to develop natural product-based HIV drug candidates

July 8, 1999

Ritonavir found to be more potent inhibitor of P-glycoprotein than SDZ-PSC-833

July 8, 1999

Trimeris begins phase I trial of second fusion inhibitor

July 7, 1999

ZymeTx returns anti-HIV compound to Oklahoma Medical Research Foundation

July 6, 1999

New small-molecule HIV protease inhibitors reported

July 6, 1999

Kissei seeks approval of amprenavir in Japan

July 5, 1999

DAPD: another promising agent for combination therapy of HIV/AIDS

July 5, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...